{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:11:03Z","timestamp":1777957863087,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis A virus (HAV) infection has traditionally occurred during early childhood in high-endemic settings but is increasingly affecting adolescents and adults in regions undergoing epidemiological transition, where improvements in sanitation delay primary exposure. Adult HAV infection is associated with more severe clinical disease, and prior work has implicated CD8\u2009+\u2009cytotoxic T lymphocyte responses and cytokine-driven bystander immune activation in hepatocyte injury; however, the immunological correlates underlying age-dependent severity in populations undergoing active epidemiological transition remain incompletely characterised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed statewide surveillance data from Kerala, India (2020\u20132024), comprising 34,118 confirmed or probable HAV cases, to characterise temporal, seasonal, and geographic trends. Within this framework, we conducted an immunological substudy of 180 patients with confirmed acute HAV infection, stratified by age at infection used as an operational proxy for early (&lt;\u200918 years) versus delayed (\u2265\u200918 years) primary exposure in a population where improvements in sanitation have progressively shifted first infection to later ages. Clinical severity, hospitalisation, liver biochemistry, peripheral CD8\u2009+\u2009T-cell responses (IFN-\u03b3 ELISPOT), plasma cytokines, and viral load were assessed. Multivariable logistic regression and sensitivity analyses were used to identify factors associated with moderate-to-severe disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Surveillance data demonstrated a marked increase in reported HAV cases after 2021, with pronounced post-monsoon seasonality and geographic clustering. In the immunological cohort, individuals infected at \u2265\u200918 years had significantly higher odds of moderate-to-severe disease compared with those infected earlier (adjusted odds ratio 8.42, 95% CI 3.21\u201322.08). Moderate-to-severe disease occurred in 69.5% of participants with delayed exposure compared with 7.7% of those with early exposure. Delayed exposure was associated with stronger peripheral CD8\u2009+\u2009T-cell IFN-\u03b3 responses and higher plasma IFN-\u03b3 and TNF-\u03b1 concentrations, alongside higher aminotransferase levels and increased hospitalisation rates. Viral load did not differ significantly between age groups. Findings were robust across multiple sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this transitioning setting, adult primary HAV infection is associated with increased clinical severity and heightened peripheral cellular immune responses, independent of viral load. These peripheral immune findings are consistent with an immune-mediated contribution to liver injury during adult HAV infection. The findings support consideration of public health strategies aimed at preventing delayed exposure, including prioritisation of childhood hepatitis A vaccination in regions experiencing similar epidemiological transitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13193-x","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:17:12Z","timestamp":1775899032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunological consequences of delayed exposure to hepatitis A virus: evidence consistent with CD8+ T-cell\u2013mediated immunopathology"],"prefix":"10.1186","volume":"26","author":[{"given":"Peter Asaga","family":"Mac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijeesh","family":"Kadukkatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew K.","family":"Brijil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philomena","family":"Airiohuodion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"13193_CR1","first-page":"766","volume":"38","author":"JJ Ott","year":"2020","unstructured":"Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. Vaccine. 2020;38:766\u201377.","journal-title":"Vaccine"},{"key":"13193_CR2","first-page":"493","volume":"97","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Hepatitis A vaccines: WHO position paper. Wkly Epidemiol Rec. 2022;97:493\u2013512.","journal-title":"Wkly Epidemiol Rec"},{"key":"13193_CR3","first-page":"e9","volume":"21","author":"KH Jacobsen","year":"2021","unstructured":"Jacobsen KH. Globalization and the changing epidemiology of hepatitis A virus infection. Lancet Infect Dis. 2021;21:e9\u201315.","journal-title":"Lancet Infect Dis"},{"key":"13193_CR4","unstructured":"GBofD2021HC. Global, regional, and national burden of hepatitis A, 1990\u20132021: a systematic analysis. Lancet Gastroenterol Hepatol. 2023;8:1024\u201338."},{"key":"13193_CR5","volume-title":"Hepatitis A fact sheet","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Hepatitis A fact sheet. Geneva: WHO; 2024."},{"key":"13193_CR6","first-page":"543","volume":"19","author":"SM Lemon","year":"2022","unstructured":"Lemon SM, Walker CM. Hepatitis A virus and hepatitis E virus: emerging and re-emerging threats. Nat Rev Gastroenterol Hepatol. 2022;19:543\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"13193_CR7","first-page":"363","volume":"20","author":"EC Shin","year":"2023","unstructured":"Shin EC, Jeong SH. Natural history, clinical manifestations, and pathogenesis of hepatitis A. Nat Rev Gastroenterol Hepatol. 2023;20:363\u201377.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"13193_CR8","first-page":"2869","volume":"38","author":"KH Jacobsen","year":"2020","unstructured":"Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: implications for vaccination policy. Vaccine. 2020;38:2869\u201375.","journal-title":"Vaccine"},{"key":"13193_CR9","first-page":"491","volume":"12","author":"E Franco","year":"2020","unstructured":"Franco E, Meleleo C, Serino L, Sorbara D. Hepatitis A epidemiology and prevention in transitional countries. World J Hepatol. 2020;12:491\u2013505.","journal-title":"World J Hepatol"},{"key":"13193_CR10","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1017\/S0950268821000352","volume":"149","author":"L Verhoef","year":"2021","unstructured":"Verhoef L, Boot HJ, Koopmans M. Shifting hepatitis A epidemiology in Europe. Epidemiol Infect. 2021;149:e47.","journal-title":"Epidemiol Infect"},{"key":"13193_CR11","first-page":"e405","volume":"5","author":"AH Havelaar","year":"2021","unstructured":"Havelaar AH, Kirk MD, Torgerson PR. Waterborne disease risks in transitional settings. Lancet Planet Health. 2021;5:e405\u201315.","journal-title":"Lancet Planet Health"},{"issue":"9","key":"13193_CR12","first-page":"1346","volume":"22","author":"KH Jacobsen","year":"2022","unstructured":"Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990\u20132020: a systematic analysis. Lancet Infect Dis. 2022;22(9):1346\u201357.","journal-title":"Lancet Infect Dis"},{"key":"13193_CR13","first-page":"198","volume":"71","author":"IR Willner","year":"2020","unstructured":"Willner IR, Uhl MD, Howard SC. Severe hepatitis A in adults: clinical characteristics and outcomes. Clin Infect Dis. 2020;71:198\u2013205.","journal-title":"Clin Infect Dis"},{"key":"13193_CR14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.31801","volume":"74","author":"RS Koff","year":"2021","unstructured":"Koff RS. Hepatitis A: clinical features and prognosis revisited. J Hepatol. 2021;74:1251\u20133.","journal-title":"J Hepatol"},{"issue":"6","key":"13193_CR15","first-page":"1021","volume":"75","author":"YJ Hutin","year":"2022","unstructured":"Hutin YJ, Pool V, Cramer EH, et al. A multistate outbreak of hepatitis A in adults: clinical severity and hospitalisation outcomes. Clin Infect Dis. 2022;75(6):1021\u20138.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"13193_CR16","first-page":"705","volume":"29","author":"JY Seo","year":"2023","unstructured":"Seo JY, Kang SH, Kim YJ, et al. Changing epidemiology of hepatitis A in South Korea: increasing incidence among young adults. Emerg Infect Dis. 2023;29(4):705\u201313.","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"13193_CR17","first-page":"142","volume":"157","author":"VA Arankalle","year":"2023","unstructured":"Arankalle VA, Sarada Devi KL, Lole KS, et al. Age-specific seroprevalence and changing pattern of hepatitis A infection in India. Indian J Med Res. 2023;157(2):142\u201350.","journal-title":"Indian J Med Res"},{"key":"13193_CR18","first-page":"e068218","volume":"376","author":"SC Matheny","year":"2022","unstructured":"Matheny SC, Kingery JE. Hepatitis A: updated clinical review. BMJ. 2022;376:e068218.","journal-title":"BMJ"},{"key":"13193_CR19","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/gutjnl-2021-324754","volume":"71","author":"EL Yoon","year":"2022","unstructured":"Yoon EL, Sinn DH, Kim JH. Changing hepatitis A epidemiology in Asia. Gut. 2022;71:1231\u20138.","journal-title":"Gut"},{"issue":"1","key":"13193_CR20","first-page":"211","volume":"79","author":"KN Ly","year":"2024","unstructured":"Ly KN, Klevens RM, Jiles RB. Trends in hepatitis A incidence and disease severity among adults in the United States, 2016\u20132023. Hepatology. 2024;79(1):211\u201320.","journal-title":"Hepatology"},{"key":"13193_CR21","volume-title":"Hepatitis A outbreaks in Europe, 2022\u20132024","author":"European Centre for Disease Prevention and Control","year":"2024","unstructured":"European Centre for Disease Prevention and Control. Hepatitis A outbreaks in Europe, 2022\u20132024. Stockholm: ECDC; 2024."},{"key":"13193_CR22","volume-title":"Viral hepatitis surveillance\u2014United States, 2023","author":"Centers for Disease Control and Prevention","year":"2024","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance\u2014United States, 2023. Atlanta: CDC; 2024."},{"key":"13193_CR23","first-page":"2084","volume":"72","author":"A Forbes","year":"2020","unstructured":"Forbes A, Williams R. Age as a determinant of outcome in hepatitis A. Hepatology. 2020;72:2084\u20136.","journal-title":"Hepatology"},{"key":"13193_CR24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1126\/science.abq3939","volume":"376","author":"A Hirai-Yuki","year":"2022","unstructured":"Hirai-Yuki A, Hensley L, McGivern DR. Host determinants of hepatitis A virus pathogenicity. Science. 2022;376:125\u201331.","journal-title":"Science"},{"key":"13193_CR25","first-page":"568","volume":"57","author":"H Cho","year":"2025","unstructured":"Cho H, Park SH, Shin EC. Redefining immune responses in hepatitis A virus infection. Exp Mol Med. 2025;57:568\u201379.","journal-title":"Exp Mol Med"},{"key":"13193_CR26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3390\/v13050861","volume":"13","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Callendret B, Chakravarti A. Mechanisms of hepatocellular injury in hepatitis A virus infection. Viruses. 2021;13:861.","journal-title":"Viruses"},{"key":"13193_CR27","first-page":"56","volume":"62","author":"RE Lanford","year":"2021","unstructured":"Lanford RE, Walker CM. Pathogenesis of hepatitis A virus infection revisited. ILAR J. 2021;62:56\u201367.","journal-title":"ILAR J"},{"key":"13193_CR28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0168-8278(20)30583-3","volume":"73","author":"I Schulte","year":"2020","unstructured":"Schulte I, Hitziger T, Giugliano S. Characterisation of CD8\u207a T-cell responses in acute hepatitis A. J Hepatol. 2020;73:1019\u201329.","journal-title":"J Hepatol"},{"key":"13193_CR29","doi-asserted-by":"crossref","first-page":"e20201529","DOI":"10.1084\/jem.20201793","volume":"218","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Callendret B, Xu D. Dominance of cellular immune responses in resolving hepatitis A. J Exp Med. 2021;218:e20201529.","journal-title":"J Exp Med"},{"key":"13193_CR30","first-page":"461","volume":"20","author":"EC Shin","year":"2020","unstructured":"Shin EC. Immune-mediated liver injury in acute viral hepatitis. Nat Rev Immunol. 2020;20:461\u201372.","journal-title":"Nat Rev Immunol"},{"key":"13193_CR31","first-page":"65","volume":"39","author":"LG Guidotti","year":"2021","unstructured":"Guidotti LG, Chisari FV. Immunobiology of liver injury in viral hepatitis. Annu Rev Immunol. 2021;39:65\u201391.","journal-title":"Annu Rev Immunol"},{"key":"13193_CR32","first-page":"1239","volume":"75","author":"J Kim","year":"2022","unstructured":"Kim J, Chang DY, Lee HW. Immune correlates of disease severity in hepatitis A. Hepatology. 2022;75:1239\u201351.","journal-title":"Hepatology"},{"key":"13193_CR33","first-page":"161","volume":"52","author":"J Kim","year":"2020","unstructured":"Kim J, Chang DY, Lee HW. Innate-like cytotoxicity of bystander-activated CD8\u207a T cells in hepatitis A. Immunity. 2020;52:161\u201373.","journal-title":"Immunity"},{"key":"13193_CR34","first-page":"1016","volume":"74","author":"AR Kim","year":"2021","unstructured":"Kim AR, Shin EC. Cytokine-mediated bystander T-cell activation in viral hepatitis. J Hepatol. 2021;74:1016\u20138.","journal-title":"J Hepatol"},{"key":"13193_CR35","first-page":"987","volume":"78","author":"PS Sung","year":"2023","unstructured":"Sung PS, Park DJ, Kim JH. Innate-like immune activation in acute viral hepatitis. Hepatology. 2023;78:987\u201399.","journal-title":"Hepatology"},{"key":"13193_CR36","first-page":"589","volume":"21","author":"B Adkins","year":"2021","unstructured":"Adkins B. Developmental immunology and viral infection outcomes. Nat Rev Immunol. 2021;21:589\u2013602.","journal-title":"Nat Rev Immunol"},{"key":"13193_CR37","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1073\/pnas.1915499117","volume":"117","author":"E Billerbeck","year":"2020","unstructured":"Billerbeck E, Kang YH, Walker LJ. Tissue-homing properties of human CD8\u207a T cells. Proc Natl Acad Sci U S A. 2020;117:3006\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13193_CR38","first-page":"100180","volume":"12","author":"P Mathur","year":"2023","unstructured":"Mathur P, Arora NK. Public health implications of hepatitis A transition in India. Lancet Reg Health Southeast Asia. 2023;12:100180.","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"13193_CR39","first-page":"1537","volume":"9","author":"PS Rakesh","year":"2020","unstructured":"Rakesh PS, Raveendran S, Siyad P. Hepatitis A outbreaks in Kerala: epidemiological features. J Family Med Prim Care. 2020;9:1537\u201341.","journal-title":"J Family Med Prim Care"},{"key":"13193_CR40","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1017\/S0950268821001485","volume":"149","author":"YK Gurav","year":"2021","unstructured":"Gurav YK, Retheesh Babu G, Lole KS. Adult hepatitis A outbreaks in South India. Epidemiol Infect. 2021;149:e199.","journal-title":"Epidemiol Infect"},{"key":"13193_CR41","first-page":"314","volume":"116","author":"G Retheesh Babu","year":"2022","unstructured":"Retheesh Babu G, Vijayakumar K, Renjini BA. Waterborne hepatitis A in Kerala. Int J Infect Dis. 2022;116:314\u201320.","journal-title":"Int J Infect Dis"},{"key":"13193_CR42","first-page":"4975","volume":"38","author":"MS Chadha","year":"2020","unstructured":"Chadha MS, Walimbe AM, Chobe LP. HAV seroprevalence trends in India. Vaccine. 2020;38:4975\u201382.","journal-title":"Vaccine"},{"key":"13193_CR43","first-page":"873","volume":"58","author":"TJ John","year":"2021","unstructured":"John TJ, Muliyil J. Waning population immunity to hepatitis A in India. Indian Pediatr. 2021;58:873\u20136.","journal-title":"Indian Pediatr"},{"key":"13193_CR44","unstructured":"Directorate of Health Services. Government of Kerala. Communicable disease surveillance report 2024. Thiruvananthapuram; 2025."},{"key":"13193_CR45","first-page":"467","volume":"153","author":"VA Arankalle","year":"2021","unstructured":"Arankalle VA, Chadha MS, Chitambar SD. Hepatitis A epidemiological transition in India. Indian J Med Res. 2021;153:467\u201376.","journal-title":"Indian J Med Res"},{"key":"13193_CR46","first-page":"1014","volume":"222","author":"WA Bower","year":"2020","unstructured":"Bower WA, Nainan OV, Han X. Duration of viraemia and immune activation in hepatitis A. J Infect Dis. 2020;222:1014\u201322.","journal-title":"J Infect Dis"},{"key":"13193_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/9781118548387","volume-title":"Applied Logistic Regression","author":"DW Hosmer","year":"2013","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd ed. Hoboken: Wiley; 2013.","edition":"3"},{"issue":"5","key":"13193_CR48","first-page":"987","volume":"78","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Callendret B, Xu D, et al. Dominant role of CD8\u207a T cells in hepatocellular injury during acute hepatitis A infection in humans. J Hepatol. 2023;78(5):987\u201397.","journal-title":"J Hepatol"},{"issue":"1","key":"13193_CR49","first-page":"62","volume":"31","author":"E Sagnelli","year":"2024","unstructured":"Sagnelli E, Coppola N, Scolastico C, et al. Clinical and immunological predictors of severe acute hepatitis A in adults: a multicentre prospective study. J Viral Hepat. 2024;31(1):62\u201371.","journal-title":"J Viral Hepat"},{"issue":"11","key":"13193_CR50","first-page":"2495","volume":"42","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Goel A. Cytokine responses and immune-mediated liver injury in acute hepatitis A: a prospective cohort study. Liver Int. 2022;42(11):2495\u2013504.","journal-title":"Liver Int"},{"issue":"3","key":"13193_CR51","first-page":"1132","volume":"77","author":"EC Shin","year":"2023","unstructured":"Shin EC, Jeong SH. Immunopathogenesis of acute viral hepatitis A: role of interferon-gamma producing T cells in disease severity. Hepatology. 2023;77(3):1132\u201344.","journal-title":"Hepatology"},{"issue":"2","key":"13193_CR52","first-page":"e1475","volume":"13","author":"JH Kim","year":"2024","unstructured":"Kim JH, Yoon EL, Park H, et al. HAV-specific cellular immune responses and cytokine activation in patients with acute hepatitis A. Clin Transl Immunol. 2024;13(2):e1475.","journal-title":"Clin Transl Immunol"},{"key":"13193_CR53","volume-title":"Kerala Human Development Report 2021","author":"Government of Kerala","year":"2022","unstructured":"Government of Kerala. Kerala Human Development Report 2021. Thiruvananthapuram: State Planning Board; 2022."},{"key":"13193_CR54","first-page":"a037259","volume":"11","author":"CM Walker","year":"2021","unstructured":"Walker CM. Adaptive immune responses in hepatitis A virus infection. Cold Spring Harb Perspect Med. 2021;11:a037259.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"18","key":"13193_CR55","first-page":"2712","volume":"41","author":"E Franco","year":"2023","unstructured":"Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: epidemiology and prevention in developing countries undergoing transition. Vaccine. 2023;41(18):2712\u20139.","journal-title":"Vaccine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13193-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:13:57Z","timestamp":1777954437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13193-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13193"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13193-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Ethics Committee of Government Medical College, Thiruvananthapuram (IEC No. 01\/32\/2020\/MCT), with reciprocal approval from the Ethics Committee of the Faculty of Medicine, University of Freiburg. Written informed consent was obtained from all participants or their legal guardians, as appropriate. Surveillance data were anonymised prior to analysis. All procedures were conducted in accordance with the Declaration of Helsinki (2013 revision) and national ethical guidelines for biomedical and health research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AI-based language tools were used solely for grammatical editing and improvement of readability. No AI tools were used to generate scientific content, interpret data, perform statistical analyses, or construct scientific arguments. All study design decisions, analyses, and conclusions are the work of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI-assisted tools"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"888"}}